Assertion Supported AI assessment confidence: 95% certainty 5/5 debate potential 4/5

Makary: FDA halted Biden-era policy allowing CAR-T cell editing in China

Dr. Marty Makary · Supercharging a New FDA: Marty Makary on Science, Power & Patients · Jan 15, 2026 · at 30:25

Dr. Marty Makary, FDA Commissioner, discusses international biotech supply chains and FDA regulatory oversight at the JP Morgan Healthcare Conference.

0:00 / 0:18exact quote · 18.5s

▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark

“We did find that there was in the Biden administration approval to have the cells of Americans for CAR T therapy shipped to China where the Chinese did the gene editing and then shipped back to the United States. To infuse in Americans. When I found out about that, we shut that thing down so fast.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

Under the Biden administration, approval was given to ship American patients' cells to China for CAR-T gene editing before returning them to the U.S., a practice FDA Commissioner Dr. Marty Makary subsequently shut down.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

Under the Biden administration, FDA-regulated Investigational New Drug (IND) approvals and a January 2025 Department of Justice rule exemption (28 CFR § 202.510) permitted clinical trials to export American patients' T-cells to Chinese manufacturing organizations for CAR-T gene editing prior to U.S. re-infusion. After becoming FDA Commissioner in April 2025, Dr. Marty Makary announced an immediate regulatory freeze on June 18, 2025, halting new approvals and suspending clinical trials that involved shipping U.S. citizens' living cells to China for genetic engineering. Both legs of the claim are fully corroborated by official FDA announcements and regulatory records.

Under 28 CFR § 202.510 (finalized January 2025), an explicit exemption permitted FDA-regulated clinical trials to export patient biological materials, including T-cells, to foreign entities in China for CAR-T cell processing and gene editing.
On June 18, 2025, the FDA under Commissioner Dr. Marty Makary issued an official press release announcing an immediate freeze and review of clinical trials exporting U.S. citizens' cells to China for genetic engineering, blocking further approvals of the practice.

Checked against

[1] federalregister.gov [2] knobbe.com [3] fda.gov [4] wikipedia.org [5] fda.gov [6] fda.gov [7] crowell.com [8] healthlawadvisor.com

Marty Makary FDA commissioner CAR-T China Marty Makary FDA CAR-T China cells "Department of Justice" "bulk data" December 2024 "clinical trials" exemption FDA "June 18, 2025" "FDA" "American citizens" living cells China "CAR-T" manufacturing China U.S. patients FDA approval "CAR-T" "China" FDA Biden administration cell editing

assessed as of 2026-07-31

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

Biden administration CAR-T therapy China FDA

⚑ Spot an error? Report it

More from Dr. Marty Makary

Opinion

FDA Chief Makary: Ignoring COVID natural immunity was 'scientifically dishonest'

“Ignoring natural immunity, one of the most scientifically dishonest things a scientist could possibly say about the virus and the immunity.”

Dr. Marty Makary Jan 15, 2026 ▶ 2:40 Supercharging a New FDA: Marty Makary on Science, Power & Patients

Disclosure

Makary: FDA reduces default drug approval requirement to one pivotal trial

“We announced just last month that we are going to go from a baseline default requirement of two pivotal trials for a drug to one pivotal trial for a drug.”

Dr. Marty Makary Jan 15, 2026 ▶ 14:13 Supercharging a New FDA: Marty Makary on Science, Power & Patients

Assertion Partly supported

Makary: The Trump administration has not cut any NIH funding

“In the Trump administration, we have not cut one dollar of NIH funding.”

Dr. Marty Makary Jan 15, 2026 ▶ 45:19 Supercharging a New FDA: Marty Makary on Science, Power & Patients

Assertion Contradicted

Makary claims 14% of all NIH grants went to DEI research

“14% of any NIH grants went to DEI research.”

Dr. Marty Makary Jan 15, 2026 ▶ 47:59 Supercharging a New FDA: Marty Makary on Science, Power & Patients

Disclosure

Makary: Federal health officials released reduced core vaccine schedule of 38 doses

“So we gave them a list that constitutes about 38 doses from age zero to 18.”

Dr. Marty Makary Jan 15, 2026 ▶ 52:52 Supercharging a New FDA: Marty Makary on Science, Power & Patients

Prediction Partly held up

Makary predicts GLP-1 drug starter pricing will drop to $149

“With the GLP-I example, for example, it's gonna come down to a 149 dollars for the first three months.”

Dr. Marty Makary Jan 15, 2026 ▶ 1:00:41 Supercharging a New FDA: Marty Makary on Science, Power & Patients

Makary: FDA halted Biden-era policy allowing CAR-T cell editing in China

More from Dr. Marty Makary

Turn any episode into a week of clips.